Read More
Coherus and Junshi Bioscience’s Loqtorzi (toripalimab-tpzi) Received the US FDA’s Approval to Treat Nasopharyngeal Carcinoma (NPC)
Read More
The US FDA Grants Santhera’s Agamree (vamorolone) Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)
Read More
Idorsia Pharmaceuticals Reports the NDA Submission of Daridorexant to the PMDA for the Treatment of Insomnia
Read More
BMS Receives EMA’s Validation of Opdivo (nivolumab) + Cisplatin-Based CT for 1L Treatment of Unresectable or Metastatic Urothelial Carcinoma
Read More
Novartis Received The US FDA’s Approval for Cosentyx to Treat Hidradenitis Suppurativa
Read More
The US FDA Approved Amgen’s Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases
Read More
Abbott’s Alinity M High Risk (HR) HPV assay for the Detection of HPV Infections has been approved by the US FDA
Read More
The US FDA has accepted to review the resubmitted NDA of Supernus’ SPN-830 for the Treatment of Off Episodes in Parkinson’s Disease
Read More
GSK Reports Positive Results of P-III Study (RUBY) for Jemperli + CT in Primary Advanced or Recurrent Endometrial Cancer Patients
Read More
Novartis’ Reports Results of Atrsentan in P-III Study for the Treatment of IgA Nephropathy
Read More
Otsuka Pharmaceutical Reports Results for Centanafadine in Two P-III Trials for the Treatment of ADHD
Read More
Teva Pharmaceutical Reports P-III Results of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia
Read More
T3D Therapeutics has announced promising outcomes from the P-II study (PIONEER) of T3D-959 in the treatment of Alzheimer’s Disease
Read More
Innate Pharma Presents P-II Study (TELLOMAK) Results of Lacutamab for the Treatment of Sézary Syndrome
Read More
Roche Reports Positive Efficacy Results from the P-III Study (EMBARK) of Elevidys for Duchenne Muscular Dystrophy (DMD)
Read More
Merck Reports Secondary Endpoint Results of Keytruda in P-III Trial for the Treatment of Renal Cell Carcinoma (RCC)
Read More
Adaptimmune Reports Positive Data from the P-II Trial Assessing Lete-cel for the Treatment of Synovial Sarcoma And Myxoid/Round Cell Liposarcoma (MRCLS)
Read More
UCB Publishes the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy in ‘Epilepsy & Behavior’
Read More
Henlius Brings Hansizhuang (serplulimab injection) to Europe and India Through an Exclusive Licensing Agreement with Accord Healthcare
Read More
Sosei Heptares Receives a Milestone Payment of $3.75M as a Part of its Multi-Target Agreement with Genentech
Read More
Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement for the Development of HRS-1167 and SHR-A1904 to Treat Cancer
Read More
Zydus and Guardant Health will Co-Promote the Guardant360 portfolio which includes Guardant360 and Guardant360 TissueNext tests for advanced solid cancers in India and Nepal
Read More
AstraZeneca Signs a Collaboration Agreement with Cellectis to Develop Novel Cell and Gene Therapies for Oncology and Immunology Indications
Read More
Abcellera and Prelude Therapeutics Entered into a Partnership to Develop ADCs Therapies for the Treatment of Cancer
Read More
Aldeyra Therapeutics Signs an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease
Read More
GSK Enters into an Agreement with Janssen and Arrowhead for JNJ-3989 to Treat Chronic Hepatitis B
Read More
Abbott Reports Trial Data for Esprit BTK Drug-Eluting Resorbable Scaffold to Treat Chronic Limb-Threatening Ischemia (CLTI)
Read More
Shorla Oncology Acquires Jylamvo form Therakind as a Therapy Targeting Oncology and Autoimmune Indications
Read More
The collaboration marks the expansion between R1 RCM and Microsoft to develop and integrate Generative AI and Revenue Cycle Management Platform
Read More
